N-[(5-bromopyrazin-2-yl)methyl]-2,3,4,5-tetrahydro-1H-1-benzazepine-7-carboxamide
C16H17BrN4O — CID 166416128
Data last refreshed: (MolForge compound catalog, from PubChem)
About N-[(5-bromopyrazin-2-yl)methyl]-2,3,4,5-tetrahydro-1H-1-benzazepine-7-carboxamide
N-[(5-bromopyrazin-2-yl)methyl]-2,3,4,5-tetrahydro-1H-1-benzazepine-7-carboxamide (PubChem CID 166416128) has the molecular formula C16H17BrN4O and a molecular weight of 361.24 g/mol. Its IUPAC name is N-[(5-bromopyrazin-2-yl)methyl]-2,3,4,5-tetrahydro-1H-1-benzazepine-7-carboxamide.
Molecular Properties
| Compound Name | N-[(5-bromopyrazin-2-yl)methyl]-2,3,4,5-tetrahydro-1H-1-benzazepine-7-carboxamide |
|---|---|
| PubChem CID | 166416128 |
| Molecular Formula | C16H17BrN4O |
| Molecular Weight | 361.24 g/mol |
| Exact Mass | 360.06 |
| IUPAC Name | N-[(5-bromopyrazin-2-yl)methyl]-2,3,4,5-tetrahydro-1H-1-benzazepine-7-carboxamide |
| SMILES | O=C(NCc1cnc(Br)cn1)c1ccc2c(c1)CCCCN2 |
| InChI | InChI=1S/C16H17BrN4O/c17-15-10-19-13(8-20-15)9-21-16(22)12-4-5-14-11(7-12)3-1-2-6-18-14/h4-5,7-8,10,18H,1-3,6,9H2,(H,21,22) |
| InChIKey | IHSUIKQVBQXQSC-UHFFFAOYSA-N |
| XLogP | 2.92 |
| TPSA | 66.91 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 4 |
| Rotatable Bonds | 3 |
| Heavy Atoms | 22 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 361.24 |
| LogP ≤ 5 | 2.92 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 4 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 166416128 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.